CompletedNCT04043988Updated May 3, 2023

Management of Diverticulitis in the Emergency Department

An observational study in Diverticulitis, sponsored by Olive View-UCLA Education & Research Institute. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-03.

Sponsored by Olive View-UCLA Education & Research Institute · Observational

Study type: Observational
Model: Case-only
Time perspective: Prospective
Enrollment: 718
Ages: 18 Years and older
Sex: All

Study summary

This study aims to describe current treatment practices in the US for managing acute uncomplicated diverticulitis. In addition, we will identify clinical factors associated with the decision to discharge versus hospitalize patients with uncomplicated diverticulitis with the goal of informing clinical decision-making and providing a foundation for diagnostic algorithms to guide clinical practice.

Conditions studied

Diverticulitis

Browse trials for

Diverticulitis 125

In context

Diverticulitis

125 studies on the registry are indexed under Diverticulitis; 22 are open to participants now.

This study's enrollment of 718 is above the median of 275 across 59 observational studies indexed under Diverticulitis.

Browse Diverticulitis studies →

Lead sponsor

Olive View-UCLA Education & Research Institute is the lead sponsor of 14 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years and older
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Non-probability sample

Study population

Patients presenting to the emergency departments at EMERGEncy ID NET sites will be screened for study eligibility by study coordinators or treating clinicians.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age ≥18 years
Emergency department presumptive or confirmed final diagnosis of acute diverticulitis
Verbal or written consent provided in English (or Spanish depending on study site)

Exclusion criteria

Exclusion Criteria:

None

Study design

Observational model: Case-only
Time perspective: Prospective
Enrollment: 718 participants (actual)
Patient registry: No

What researchers measure

Primary outcomes

Rates of hospital admission
Rates of hospital admission from the emergency department among patients being treated for acute diverticulitis will be determined. In addition, factors associated with hospital admission will be examined.
Time frame: Day 1
Rate of Imaging
The rate of imaging performed in the emergency department among patients treated for acute diverticulitis will be determined. Factors associated with imaging will also be examined.
Time frame: Day 1

Study locations

1 site

Olive View-UCLA Medical Center
Sylmar, California 93142, United States

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

Timeline

Tracking since Sep 25, 2026

ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Aug 2022, 40 months.

Of 22 observational studies under Diverticulitis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 101. This study's 40 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered: Aug 1, 2019
First posted: Aug 2, 2019
StartActual: Apr 18, 2019
Primary completionActual: Aug 30, 2022
CompletionActual: Apr 30, 2023
Last update: May 3, 2023

What these dates mean

Start.: When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.: When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.: When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.: Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.

No changes since tracking began. The registry record was last updated on May 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT04043988
Lead sponsor: Olive View-UCLA Education & Research Institute
Collaborators: Centers for Disease Control and Prevention
Responsible party: David A. Talan (Principal Investigator, Olive View-UCLA Education & Research Institute) — Principal investigator
First posted: Aug 2, 2019
Start date: Apr 18, 2019
Primary completion: Aug 30, 2022
Completion: Apr 30, 2023
Last update: May 3, 2023

Oversight

Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Diverticulitis →

Other studies from this sponsor

Olive View-UCLA Education & Research Institute

Start the discussion